It's already being given the go ahead by U.

S authorities in clinical trials.

The vaccine proved around 95% effective at preventing illness.

It was not found to cause any serious safety issues.

Experts say the U.

S firms product should also be effective against the mutated variant off the virus found in the UK Some officials in EU member states have criticized Emma for being slow to grant approvals.

Now the modern offering is the second vaccine it's okayed.

Hundreds of thousands of Europeans have already received a rival inoculation produced by Pfizer and by on tech in the U.

K.

Regulators have also approved a version developed by AstraZeneca and the University of Oxford.

On Wednesday, the Netherlands became one of the last places in the U to start conducting vaccinations.